The hyperactivation of CXCL12/CXCR4 in cancer cells compared to their normal counterparts makes this axis a promising target for targeted therapy of cancer cells (Chatterjee et al. 2014; Scotton et al. 2001, 2002). This evidence concerns the gene CXCL12 and cancer.